RTP Mobile Logo
Glioblastoma Tumor Panel and Journal Club: Clinical Investigators Provide Perspectives on Current Cases from Their Practices and Important Recent Publications and Presentations
Released March 2016

Proceedings from a satellite symposium during the 20th Annual Meeting of the Society for Neuro-Oncology. Including perspectives from Drs Minesh Mehta, Tom Mikkelsen, Jeffrey Raizer, Zvi Ram and Patrick Y Wen. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for neuro-oncologists, neurosurgeons, basic scientists and other neuro-oncology specialists involved in the treatment of primary and metastatic central nervous system cancer.

    OVERVIEW OF ACTIVITY
    Current management of high-grade malignant gliomas involves an interdisciplinary approach, integrating the knowledge and expertise of neurosurgeons, radiation oncologists, neuroradiologists, neuro-oncologists and medical oncologists. The historical mainstay of initial therapy for glioblastoma multiforme (GBM) has included surgical resection, when feasible, and postoperative radiation therapy. Despite the substantial contribution of effective chemoradiation therapy to the current glioma treatment algorithm, treatment of these tumors remains a clinical challenge to physicians. Median progression-free and overall survival times achieved continue to be suboptimal, at 6.9 and 14.6 months, respectively, and recurrent disease is virtually inevitable and carries a poor prognosis.

    However, recent advances in the understanding of glioma pathophysiology and mechanisms of resistance to standard chemotherapeutics in addition to improvements in medication delivery across the blood-brain barrier have offered opportunities to enhance available treatment options. Furthermore, a number of efforts are ongoing in an attempt to find new therapies that may eventually confer increased quantity and quality of life for patients with brain cancer. Integrating these findings into routine clinical care, extrapolating data among histologic subtypes and communicating the benefits and risks of novel regimens to patients represent a challenge for treating clinicians. To bridge the gap between research and patient care, these proceedings from a CME symposium during the 20th Annual Meeting of the Society for Neuro-Oncology use the perspectives of leading neuro-oncologists and neurosurgeons to apply evidence-based concepts to routine practice. By providing information on the latest research developments in the context of expert perspectives, this activity assists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Ensure delivery of appropriate treatment for patients with primary brain cancer through facilitation of a multidisciplinary care plan.
    • Use clinical and molecular markers to assess disease prognosis and guide treatment selection, when appropriate, for patients with GBM.
    • Apply the results of existing and emerging research to the evidence-based use of chemotherapy and adjuvant chemoradiation therapy.
    • Communicate the benefits and risks of bevacizumab, both with and without chemotherapy, to patients with recurrent GBM.
    • Discuss with patients the incidence and presentation of common bevacizumab-associated adverse effects, and recommend management strategies to address tolerability issues.
    • Recall available efficacy and safety data with the use of the NovoTTF-100A system for patients with newly diagnosed and recurrent GBM in order to make an informed decision regarding its incorporation into clinical practice.
    • Recognize techniques to distinguish true disease progression from radiologic pseudoprogression among patients with treated brain tumors.
    • Describe the scientific rationale and recent research results that support ongoing investigation of novel treatments for brain cancer.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Minesh Mehta, MD
    Professor, Radiation Oncology
    University of Maryland
    Baltimore, Maryland

    Board of Directors: Pharmacyclics Inc; Consulting Agreements: Cavion, Novartis Pharmaceuticals Corporation, Novocure; Research Grant: Cellecta Inc, Novocure.

    Tom Mikkelsen, MD
    Herrick Chair in Neuro-Oncology Research
    Co-Director
    Hermelin Brain Tumor Center
    Departments of Neurology and Neurosurgery
    Henry Ford Hospital
    Detroit, Michigan

    Advisory Committee: Genentech BioOncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation.

    Jeffrey Raizer, MD
    Director, Medical Neuro-Oncology
    Professor of Neurology
    Robert H Lurie Comprehensive Cancer Center
    Northwestern University
    Feinberg School of Medicine
    Chicago, Illinois

    Advisory Committee: AbbVie Inc, Agenus Inc, Bristol-Myers Squibb Company, Foundation Medicine, Genentech BioOncology, Midatech Pharma, Novocure, Stemline Therapeutics Inc; Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Genentech BioOncology; Speakers Bureau: Genentech BioOncology.

    Zvi Ram, MD
    Chairman
    Department of Neurosurgery
    The Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel

    Advisory Committee, Consulting Agreement, Contracted Research and Ownership Interest: Novocure.

    Patrick Y Wen, MD
    Director, Center for Neuro-Oncology
    Dana-Farber/Brigham and Women’s Cancer Center
    Professor of Neurology
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Cavion, Celldex Therapeutics, Genentech BioOncology, Merck, Midatech Pharma, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Novocure, Roche Laboratories Inc, Sigma-Tau Pharmaceuticals Inc, Vascular Biogenics Ltd; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Contracted Research: Agios Pharmaceuticals, Angiochem, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Genentech BioOncology, GlaxoSmithKline, Karyopharm Therapeutics, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Vascular Biogenics Ltd; Speakers Bureau: Merck.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Genentech BioOncology and Novocure.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: March 2016
    Expiration date: March 2017

Acknowledge and close

View video:
param name="playerID" value="4790345415001" />